Sign In
Buy AORT
$26.83
-0.84 (-3.04%)
At Close: Jul 31, 2026
Time to Buy These Medical Stocks as Earnings Approach
08:39pm, Monday, 14'th Aug 2023
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.
Does Artivion (AORT) Have the Potential to Rally 52.78% as Wall Street Analysts Expect?
11:30am, Thursday, 10'th Aug 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 52.8% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the posit
Artivion, Inc. (AORT) Q2 2023 Earnings Call Transcript
01:28pm, Saturday, 05'th Aug 2023
Artivion, Inc. (NYSE:AORT ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 AM ET Company Participants Laine Morgan – Gilmartin Group Pat Mackin – Chief Executive Officer Ashley Lee – Chief
Artivion (AORT) Q2 Earnings and Revenues Top Estimates
07:32pm, Thursday, 03'rd Aug 2023
Artivion (AORT) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.03 per share a year ago.
Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)
10:16pm, Wednesday, 19'th Jul 2023
Artivion, Inc. has begun to recover from the fallout after its PROACT trial failure. On-X sales almost doubled the 5-year average range in Q1, and management look to 15% CAGR in sales moving forward.
Artivion, Inc. (AORT) Q1 2023 Earnings Call Transcript
11:49am, Sunday, 07'th May 2023
Artivion, Inc. (NYSE:AORT ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President, Gilmartin Group Pat Mackin - Chief Executive Officer Ashley Le
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2023 Financial Results
04:10pm, Thursday, 20'th Apr 2023
ATLANTA , April 20, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2023 financial result
Artivion: Reaffirm Hold As Pressures To Growth Remain
04:57am, Thursday, 20'th Apr 2023
Artivion: Reaffirm Hold As Pressures To Growth Remain.
Why Artivion Stock Popped on Friday
07:31pm, Friday, 17'th Feb 2023
There's nothing like an upside earnings surprise to juice the price of a company's shares.
Artivion, Inc. (AORT) Q4 2022 Earnings Call Transcript
09:42pm, Thursday, 16'th Feb 2023
Artivion, Inc. (NYSE:AORT ) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ET Company Participants Brian Johnston - Vice President at Gilmartin Group Pat Mackin - Chairman, President & CEO
Artivion (AORT) Q4 Earnings Surpass Estimates
07:34pm, Thursday, 16'th Feb 2023
Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2022 Financial Results
08:30am, Thursday, 02'nd Feb 2023
ATLANTA , Feb. 2, 2023 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 fi
Artivion (AORT) Upgraded to Buy: What Does It Mean for the Stock?
01:33pm, Friday, 25'th Nov 2022
Artivion (AORT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Artivion, Inc. (AORT) Q3 2022 Earnings Call Transcript
05:02pm, Saturday, 05'th Nov 2022
Artivion, Inc. (NYSE:AORT ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sam Bentzinger - Gilmartin Group Pat Mackin - Chairman, President & CEO Ashley Lee - EVP &
Artivion (AORT) Reports Q3 Loss, Tops Revenue Estimates
08:20pm, Thursday, 03'rd Nov 2022
Artivion (AORT) delivered earnings and revenue surprises of 54.55% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
